Advances in lung cancer treatment have changed survival in ways that were unimaginable even a decade ago. Targeted drugs, ...

This study presents a comprehensive approach for assessing multiple quality attributes of antibody-oligonucleotide conjugates ...

You may have heard of the consulting firm Gartner’s technology hype cycle—the technology trigger, the peak of inflated expectations, the trough of disillusionment, the slope of enlightenment, and the ...

The field of oncology has seen transformative advancements with the development of antibody-drug conjugates (ADCs), which are rapidly revolutionizing the treatment of several cancer types, including ...

Key market opportunities in next-generation drug conjugates are driven by their precision in targeting rare diseases and cancers, owing to their enhanced clinical profiles and varied targeting agents ...

Global Cancer Antibody Drug Conjugates Market poised to exceed USD 70 billion by 2031, driven by over 20 approved drugs. Report offers insights into market size, sales, pricing, and clinical trials ...

AJMC Insights Series features Kathleen Moore, MD, MS, a gynecologic oncologist and expert in ovarian cancer treatment. Dr Moore discusses various aspects of novel therapies for ovarian cancer ...

Trastuzumab deruxtecan in frontline maintenance Dr Moore discussed the challenge of prioritizing biomarkers when multiple are present: “I would always prioritize a ...

The global cancer antibody drug conjugates market is experiencing significant expansion, with a projected increase from $8.19 billion in 2024 to $9.17 billion in 2025, reflecting ...

The ADC market offers significant growth opportunities driven by the rising cancer incidence and demand for targeted ...

The conjugate space is evolving fast - moving beyond traditional ADCs into new formats like degrader-conjugates, oligonucleotide conjugates, bispecific ADCs, and more. The 4 th Novel Conjugates Summit ...